Ranitidine - Zantac is available in three forms, Tablets (150 mg, 300 mg), Capsules (150 mg, 300 mg) and Syrup (15 mg/ml). &5 mg has been accepted and widely prescribe worldwide by physicians and pharmacists for the treatment of ulcer. U.S. Food and Drug Administration (USFDA) final approval for its reduced new drug of ranitidine which is 150mg tablet, it is a generic version of Zantac for stomach disorder manufactured by GlaxoSmithKline's. Initially Zantac was available in 75 mg and now after excessive clinical trials this pill finally approved for present and future treatment. Ranitidine, which is used particularly in the treatment of ulcer, can work more effectively.


The 25-mg tablet cab be dissolved in at least 5 mL of water and then given to the infant or child. In new release the company has given description about it that the taste of the tablet formulation is more favored by the children over Ranitidine - Zantac syrup and which is also a convenient dose for patients whose weight is between 11 to 22 lb. The FDA approval for Ranitidine represents one of the most significant product launches in the U.S. market. About the 180-day marketing uniqueness and it is planned to take full advantage of the exclusive position to realize the trading potential of the product in the market. FDA approved this drug despite its side effects obviously because every medicine has one or many and they happen in most rare cases of negligence.